Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Here’s Why TESARO Inc (TSRO) Fell Sharply

Shares of TESARO Inc (NASDAQ:TSRO) are off almost 10% in afternoon trading on Thursday after the company announced the wholesale cost of 30 pills of ZEJULA 200mg at around $9833 per month. When incorporating the recommended dose of 300mg, that translates to a price of around $14,700 per month. The FDA gave the thumbs up to Zejula, which is approved for the maintenance treatment of adult patients with certain types of recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, in March and many investors have high expectations. Due to various fees, the net price of the drug is somewhat lower than what many on Wall Street were expecting. In part due to the softer pricing, several analysts downgraded TESARO Inc (NASDAQ:TSRO). Seamus Fernandez of Leerink lowered his target to $158 from $186, while Robyn Karnauskas of Citi cut her target to $216 from $232. The downgrades likely caused a lot of the selling.

What Does The Smart Money Sentiment Say?

At Insider Monkey, we’ve developed an investment strategy that has delivered market-beating returns over the past 12 months. Our strategy identifies the 100 best-performing funds of the previous quarter from among the collection of 700+ successful funds that we track in our database, which we accomplish using our returns methodology. We then study the portfolios of those 100 funds using the latest 13F data to uncover the 30 most popular mid-cap stocks (market caps of between $1 billion and $10 billion) among them to hold until the next filing period. This strategy delivered 39.7% gains over the past 12 months and outperformed the 24.1% gain enjoyed by the S&P 500 ETFs. Our enhanced small-cap hedge fund strategy returned more than 45% over the last 12 months and outperformed SPY by more than 30 percentage points over the last 4.5 years (see details here).

The smart money wasn’t super optimistic on TESARO in Q4. Of the 742 funds we track, 30 reported having a bullish position in TESARO Inc (NASDAQ:TSRO) at the end of December, down 6 funds from the previous quarter.

The Bottom Line

TESARO Inc (NASDAQ:TSRO) shares are down due to Wall Street downgrades after the company priced ZEJULA at a lower-than-expected level. For those of you interested, read ‘10 Countries That Export The Most Drugs in the World‘.

Follow Tesaro Inc. (NASDAQ:TSRO)
Trade (NASDAQ:TSRO) Now!

Disclosure:None

igorstevanovic/Shutterstock.com

igorstevanovic/Shutterstock.com